Drug Profile
Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical
Alternative Names: ABT-492; Baxdela; Quofenix; RX-3341; RX-3341-83; WQ-3034Latest Information Update: 12 Jul 2023
Price :
$50
*
At a glance
- Originator Wakunaga Pharmaceutical
- Developer Abbott Laboratories; Eurofarma; Melinta Therapeutics; Menarini
- Class Anti-infectives; Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia; Skin and soft tissue infections
- Preclinical Tularaemia
- No development reported Urinary tract infections
- Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections
Most Recent Events
- 10 Jul 2023 Melinta Therapeutics receives BARDA grant for delafloxacin development in Community-acquired bacterial pneumonia
- 10 Jul 2023 Melinta Therapeutics plans to submit sNDA for Community-acquired bacterial pneumonia (In adolescents, In children)
- 15 Jun 2023 Pharmacodynamics data from preclinical studies in Plague presented at the ASM Microbe (ASMM-2023)